Novartis AG ADR (NVS)vsTscan Therapeutics Inc (TCRX)
NVS
Novartis AG ADR
$158.83
-0.25%
HEALTHCARE · Cap: $290.96B
TCRX
Tscan Therapeutics Inc
$0.74
-4.19%
HEALTHCARE · Cap: $59.78M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 620445% more annual revenue ($56.69B vs $9.14M). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
TCRX
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$158.83
$66.29 premium
Intrinsic value data unavailable for TCRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : TCRX
The strongest argument for TCRX centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : TCRX
The primary concerns for TCRX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
TCRX carries more volatility with a beta of 1.04 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 30/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Tscan Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor (TCR) discovery platform. The firm is dedicated to developing a diverse pipeline of TCR-based therapeutics targeting specific cancer antigens, with the objective of enhancing patient outcomes across various malignancies. With a strong intellectual property portfolio and a strategic emphasis on T cell-based immunotherapies, Tscan is well-positioned to meet significant unmet medical needs in the oncology sector, standing out in a competitive and rapidly evolving market.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?